Lipodystrophy Associated with an HIV-Protease Inhibitor

  • Carr A
  • Cooper D
92Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Figure 1. A 53-year-old man had human immunodeficiency virus (HIV)–related lymphoma, which had been in remission since 1987; a CD4+ lymphocyte count of 510 cells per cubic millimeter; and an HIV RNA load of 5000 copies per milliliter. The addition of the HIV-protease inhibitor indinavir (800 mg three times daily) to his antiretroviral regimen of zidovudine and lamivudine resulted in a decrease in the HIV RNA load to undetectable levels and an increase in the CD4+ count to 918 cells per cubic millimeter. Measurement of cholesterol (298 mg per deciliter [7.7 mmol per liter]; reference range, <193 mg per deciliter . . .

Cite

CITATION STYLE

APA

Carr, A., & Cooper, D. A. (1998). Lipodystrophy Associated with an HIV-Protease Inhibitor. New England Journal of Medicine, 339(18), 1296–1296. https://doi.org/10.1056/nejm199810293391806

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free